United States· US:0378-6172_80dfdc38-4f24-4670-9341-bee52a95fd49

Metolazone

A metolazone product containing metolazone, registered in United States by Mylan Pharmaceuticals Inc.. The same ATC class is registered in 10 of our 19 countries.

ATC C03BA08US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedMetolazoneATCC03BA08REGISTER NO.US:0378-6172_80dfdc38…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Metolazone is registered in 10 of 19 countries.

Countries holding a registration under ATC C03BA08 (metolazone), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 6 of them publish a price we can compare per daily dose

Metolazone · ATC C03BA08

10 / 19 countries

  • Canada
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Norwayprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of metolazone costs, country by country.

Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.19 in Italy to $1.25 in Switzerland — a ×6.5 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Metolazone · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.25
  • IT Italy$0.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
METOLAZONE
Manufacturer
Mylan Pharmaceuticals Inc.
Country
United States (US)
ATC code
C03BA08
ATC class
Metolazone
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    0378617201
    100 TABLET in 1 BOTTLE, PLASTIC (0378-6172-01)
  • ndc11
    0378-6172-01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

326 interactions on record for metolazone.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Metolazone · interactions on record

326 records

  • 4 severe
  • 208 moderate
  • 19 minor
  • 91 info

Most severe, free to view

  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • Aminolevulinic acidL01XD04severe
  • Arsenic trioxideL01XX27severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Metolazone in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metolazone products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Denmark · Metolazon Abcur
  • Finland · Metolazon Abcur
  • United Kingdom (Northern Ireland) · Meturix, Xaqua
  • Iceland · Metolazon Abcur
  • Italy · Zaroxolyn
  • Norway · Metolazon Abcur
  • Portugal · Diulo
  • Sweden · Metolazon Abcur

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/be120ce1-f1c8-42d8-b488-e1934e60b058
GET /v1/drugs/be120ce1-f1c8-42d8-b488-e1934e60b058?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "2.5",
  "substance": "METOLAZONE",
  "productndc": "0378-6172",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA076698",
  "marketing_category": "ANDA"
}

See everything about metolazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.